Literature DB >> 30657881

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Sare Verstockt1, Gert De Hertogh2,3, Jan Van der Goten4, Bram Verstockt4,5, Maaike Vancamelbeke4, Kathleen Machiels4, Leentje Van Lommel6, Frans Schuit6, Gert Van Assche4,5, Paul Rutgeerts4,5, Marc Ferrante4,5, Séverine Vermeire4,5, Ingrid Arijs4,7, Isabelle Cleynen1.   

Abstract

BACKGROUND AND AIMS: Early treatment of Crohn's disease [CD] is required in order to optimize patient outcomes. To this end, we need to gain a better understanding of the molecular changes at the onset of CD.
METHODS: As a model for the earliest mucosal CD lesions, we study post-operative recurrent CD [Rutgeerts score ≥ i2b]. We are the first to analyse gene and microRNA [miRNA] expression profiles in ileal biopsies from these patients, and compare them with those of newly diagnosed [≤18 months] and late-stage [>10 years after diagnosis] CD patients.
RESULTS: Except for one gene [WNT5A], there are no differential genes in CD patients without post-operative recurrence [i0], showing that previous disease did not influence gene expression in the neoterminal ileum, and that this model can be used to study early mucosal CD lesions. Gene expression and co-expression network dysregulation is more pronounced in newly diagnosed and late-stage CD than in post-operative recurrent CD, with most important modules associated with [a]granulocyte adhesion/diapedesis, and cholesterol biosynthesis. In contrast, we found a role for snoRNAs/miRNAs in recurrent CD, highlighting the potential importance of regulatory RNAs in early disease stages. Immunohistochemistry confirmed the expression of key dysregulated genes in damaged/regenerating epithelium and immune cells in recurrent CD.
CONCLUSIONS: Aside from regulatory RNAs, there are no clear gene signatures separating post-operative recurrent, newly diagnosed, and late-stage CD. The relative contribution of dysregulated genes and networks differs, and suggests that surgery may reset the disease at the mucosal site, and therefore post-operative recurrent CD might be a good model a good model to study to study early mucosal CD lesions.
Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Early Crohn’s disease; gene expression; gene regulation; molecular mechanisms

Year:  2019        PMID: 30657881     DOI: 10.1093/ecco-jcc/jjz007

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  16 in total

1.  Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.

Authors:  Sare Verstockt; Bram Verstockt; Kathleen Machiels; Maaike Vancamelbeke; Marc Ferrante; Isabelle Cleynen; Gert De Hertogh; Séverine Vermeire
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 5.325

2.  Identification of Immune Cell Landscape and Construction of a Novel Diagnostic Nomogram for Crohn's Disease.

Authors:  Hong Chen; Chunqiu Chen; Xiaoqi Yuan; Weiwei Xu; Mu-Qing Yang; Qiwei Li; Zhenyu Shen; Lu Yin
Journal:  Front Genet       Date:  2020-04-29       Impact factor: 4.599

Review 3.  MicroRNAs overexpressed in Crohn's disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn's disease pathogenesis.

Authors:  Cecilia Fernández-Ponce; Roberto Navarro Quiroz; Anderson Díaz Perez; Gustavo Aroca Martinez; Andrés Cadena Bonfanti; Antonio Acosta Hoyos; Lorena Gómez Escorcia; Sandra Hernández Agudelo; Christian Orozco Sánchez; José Villarreal Camacho; Linda Atencio Ibarra; Jose Consuegra Machado; Alberto Espinoza Garavito; Francisco García-Cózar; Elkin Navarro Quiroz
Journal:  Clin Epigenetics       Date:  2021-02-18       Impact factor: 6.551

4.  Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis.

Authors:  Ingunn Bakke; Gunnar Andreas Walaas; Torunn Bruland; Elin Synnøve Røyset; Atle van Beelen Granlund; Celia Escudero-Hernández; Silje Thorsvik; Andreas Münch; Arne Kristian Sandvik; Ann Elisabet Østvik
Journal:  J Gastroenterol       Date:  2021-08-19       Impact factor: 7.527

Review 5.  Network Biology Approaches to Achieve Precision Medicine in Inflammatory Bowel Disease.

Authors:  John P Thomas; Dezso Modos; Tamas Korcsmaros; Johanne Brooks-Warburton
Journal:  Front Genet       Date:  2021-10-21       Impact factor: 4.599

6.  Paneth Cell Alertness to Pathogens Maintained by Vitamin D Receptors.

Authors:  Rong Lu; Yong-Guo Zhang; Yinglin Xia; Jilei Zhang; Arthur Kaser; Richard Blumberg; Jun Sun
Journal:  Gastroenterology       Date:  2020-11-18       Impact factor: 22.682

7.  Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.

Authors:  Bram Verstockt; Sare Verstockt; Saeed Abdu Rahiman; Bo-Jun Ke; Kaline Arnauts; Isabelle Cleynen; João Sabino; Marc Ferrante; Gianluca Matteoli; Séverine Vermeire
Journal:  J Crohns Colitis       Date:  2021-03-05       Impact factor: 9.071

8.  Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis.

Authors:  Ho-Su Lee; Maaike Vancamelbeke; Sare Verstockt; Tom Wilms; Bram Verstockt; João Sabino; Marc Ferrante; Séverine Vermeire; Isabelle Cleynen
Journal:  Cells       Date:  2020-07-28       Impact factor: 6.600

9.  Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.

Authors:  Inés Moret-Tatay; Elena Cerrillo; David Hervás; Marisa Iborra; Esteban Sáez-González; Javier Forment; Luis Tortosa; Pilar Nos; Jose Gadea; Belén Beltrán
Journal:  Clin Transl Gastroenterol       Date:  2021-10-25       Impact factor: 4.488

Review 10.  Big data in IBD: big progress for clinical practice.

Authors:  Nasim Sadat Seyed Tabib; Matthew Madgwick; Padhmanand Sudhakar; Bram Verstockt; Tamas Korcsmaros; Séverine Vermeire
Journal:  Gut       Date:  2020-02-28       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.